WHO Archives - Page 3 of 3

Home
/
Projects
/

WHO

Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes

2019

The preferred product characteristics (PPC) for therapeutic TB vaccines described in this document are intended to provide guidance to scientists, funding agencies, public and private sector organizations developing such vaccine candidates. This document presents potential clinical end-points for ev idence generation and discusses key considerations about potential clinical development strategies

The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study

2023

Hypothetical vaccines

Completed

We estimated the impact of novel tuberculosis vaccines in low-income and middle-income countries (LMICs) in several delivery scenarios.

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study

2023

Hypothetical vaccines

Completed

We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies.

The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries

2023

Hypothetical vaccines

Completed

We assessed the potential financial risk protection from introducing novel TB vaccines, and how health and economic benefits would be distributed across income quintiles.

What do people want?

2024

Hypothetical vaccines

Planned

Investigate current TB prevention modalities vs vaccine. We lack understanding of preferences and trade offs people would be willing to make across a spectrum of issues related to study design, type of vaccines, how they are given, how often, where they are given, to whom, efficacy estimates and side effects etc.

TPTVaxx

2024

Planned

Vaccines will be introduced in contexts where TPT already exists. Exploration of possible study designs, expected effectiveness, feasibility of integrated approaches is key.

An investment case for new tuberculosis vaccines

2022

Hypothetical vaccines

Completed

This document summarizes the results of the WHO-commissioned full value proposition for new TB vaccines. It is for use by national and global decision-makers involved in vaccine development and implementation.